HK1055963A1 - Valsartan salts - Google Patents

Valsartan salts

Info

Publication number
HK1055963A1
HK1055963A1 HK03108267.6A HK03108267A HK1055963A1 HK 1055963 A1 HK1055963 A1 HK 1055963A1 HK 03108267 A HK03108267 A HK 03108267A HK 1055963 A1 HK1055963 A1 HK 1055963A1
Authority
HK
Hong Kong
Prior art keywords
valsartan
salts
valsartan salts
Prior art date
Application number
HK03108267.6A
Other languages
English (en)
Inventor
Erwin Marti
Hans Rudolf Oswald
Peter Buehlmayer
Wolfgang Marterer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1055963(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1055963A1 publication Critical patent/HK1055963A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
HK03108267.6A 2000-07-19 2003-11-13 Valsartan salts HK1055963A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00115556 2000-07-19
PCT/EP2001/008253 WO2002006253A1 (en) 2000-07-19 2001-07-17 Valsartan salts

Publications (1)

Publication Number Publication Date
HK1055963A1 true HK1055963A1 (en) 2004-01-30

Family

ID=8169294

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03108267.6A HK1055963A1 (en) 2000-07-19 2003-11-13 Valsartan salts

Country Status (31)

Country Link
US (5) US20030207930A1 (xx)
EP (1) EP1313714B1 (xx)
JP (1) JP4102664B2 (xx)
KR (1) KR100529658B1 (xx)
CN (2) CN1216873C (xx)
AR (2) AR032758A1 (xx)
AT (1) ATE406355T1 (xx)
AU (2) AU2001289672B2 (xx)
BR (1) BR0112665A (xx)
CA (1) CA2415962C (xx)
CY (1) CY1108559T1 (xx)
CZ (1) CZ303389B6 (xx)
DE (1) DE60135560D1 (xx)
DK (1) DK1313714T3 (xx)
EC (1) ECSP034436A (xx)
ES (1) ES2309090T3 (xx)
HK (1) HK1055963A1 (xx)
HU (1) HU229280B1 (xx)
IL (2) IL153882A0 (xx)
MX (1) MXPA03000525A (xx)
MY (2) MY152846A (xx)
NO (1) NO326504B1 (xx)
NZ (1) NZ523557A (xx)
PE (1) PE20020613A1 (xx)
PL (1) PL205715B1 (xx)
PT (1) PT1313714E (xx)
RU (1) RU2275363C2 (xx)
SI (1) SI1313714T1 (xx)
SK (1) SK287558B6 (xx)
WO (1) WO2002006253A1 (xx)
ZA (1) ZA200300285B (xx)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2415962C (en) 2000-07-19 2010-07-06 Novartis Ag Valsartan salts
RU2334513C3 (ru) * 2002-01-17 2017-10-24 Новартис Аг Фармацевтические композиции, включающие валсартан и ингибиторы нейтральной эндопептидазы (nep)
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
AU2003223637A1 (en) * 2002-04-15 2003-11-03 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
PL373202A1 (en) * 2002-05-17 2005-08-22 Novartis Ag Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
CA2486557A1 (en) * 2002-06-13 2003-12-24 Novartis Ag Calcium salts of indole derived statins
GB0222056D0 (en) * 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
CA2519490A1 (en) * 2003-03-17 2004-09-30 Teva Pharmaceutical Industries Ltd Polymorphis of valsartan
EP1950204A1 (en) 2003-03-17 2008-07-30 Teva Pharmaceutical Industries Ltd. Amorphous form of valsartan
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
US20050165075A1 (en) * 2003-03-31 2005-07-28 Hetero Drugs Limited Novel amorphous form of valsartan
WO2004094392A1 (en) 2003-04-21 2004-11-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valsartan
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
WO2006002983A1 (en) * 2004-07-06 2006-01-12 Novartis Ag Combination of organic compounds
EP2033629B1 (en) * 2004-12-24 2012-11-14 Krka Solid pharmaceutical composition comprising valsartan
EP1674080A1 (en) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
GB0503062D0 (en) * 2005-02-14 2005-03-23 Novartis Ag Combination of organic compounds
EP1896433A4 (en) * 2005-05-25 2010-06-02 Ipca Lab Ltd NOVEL CRYSTALLINE FORMS OF (S) -N- (1-CARBOXY-2-METHYL-PROP-1-YL) -N-PENTANOYL-N- [2 '- (1H-TETRAZOL-5-YL) BI-PHENYL-4 ylmethyl] amine
FR2886642B1 (fr) * 2005-06-06 2008-05-30 Sanofi Aventis Sa Sels alcalino-terreux d'irbesartan et leur preparation
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
RU2459809C2 (ru) * 2005-11-09 2012-08-27 Новартис Аг Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
WO2007071750A1 (en) * 2005-12-22 2007-06-28 Enantia, S.L. Intermediates and processes for the preparation of valsartan
WO2008035364A2 (en) * 2006-06-23 2008-03-27 Usv Limited Process for the preparation of micronized valsartan
WO2008018843A1 (en) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Process for producing useful salts form of biphenyl-tetrazole compounds
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
JP2010526126A (ja) * 2007-05-07 2010-07-29 シプラ・リミテッド バルサルタンの製造方法
ES2312162T3 (es) * 2007-06-07 2009-02-16 Inke, S.A. Procedimiento para la obtencion de una sal de valsartan util para la preparacion de valsartan.
EP2209786B1 (en) * 2007-10-05 2013-02-27 Verastem, Inc. Pyrimidine substituted purine derivatives
FI3067043T3 (fi) 2007-11-06 2023-03-18 Novartis Ag Angiotensiinireseptoriantagonistin/-salpaajan (arb) ja neutraalin endopeptidaasin (nep) estäjän superrakenteisiin perustuvia farmaseuttisia koostumuksia
WO2009064681A2 (en) 2007-11-12 2009-05-22 Novartis Ag Liquid compositions comprising valsartan
SG187007A1 (en) 2010-08-03 2013-02-28 Novartis Ag Highly crystalline valsartan
WO2012056294A1 (en) 2010-10-29 2012-05-03 Jubilant Life Sciences Ltd. An improved process for the preparation of n-pentanoyl-n-[[2'-(1h-tetrazol-5-yi)[1,1'-biphenyl]-4-yi]methyl]-l-valine
JP5981940B2 (ja) * 2011-01-20 2016-08-31 ジエンス ハンセン ファーマセウティカル カンパニー リミテッド アジルサルタン有機アミン塩、その製造方法及び使用
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
EP2961734B1 (en) 2013-02-28 2018-09-26 Dermira, Inc. Glycopyrrolate salts
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2017042700A1 (en) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
CN105541741A (zh) * 2016-01-14 2016-05-04 青岛友诚高新技术有限公司 一种具有治疗冠心病活性的化合物及其制备方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN106243056A (zh) * 2016-07-29 2016-12-21 陈欣怡 一种缬沙坦的新型固体形式
TWI648267B (zh) * 2016-09-02 2019-01-21 諾瑞特國際藥業股份有限公司 纈沙坦二鈉鹽新晶型
US10745363B2 (en) 2016-09-02 2020-08-18 Nanjing Noratech Pharmaceuticals Co., Ltd Crystal forms of valsartan disodium salt
US10995060B2 (en) 2016-10-28 2021-05-04 Biocon Limited Amorphous Trisodium Sacubitril Valsartan and process for its preparation
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
WO2019008485A1 (en) 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
PL3658122T3 (pl) 2017-07-28 2021-10-18 Synthon B.V. Kompozycja farmaceutyczna zawierająca sakubitryl i walsartan
US20200276129A1 (en) 2017-10-13 2020-09-03 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Tablet containing valsartan and sacubitril
EP3498698A1 (en) 2017-12-15 2019-06-19 Mankind Pharma Ltd Solid forms of valsartan disodium and process of preparation thereof
CN108794418A (zh) * 2018-09-18 2018-11-13 中国药科大学 一种缬沙坦烟酰胺共无定形物
EP3766484B1 (en) 2019-07-19 2021-08-25 Zentiva, K.S. Solid pharmaceutical dosage form comprising valsartan and sacubitril
WO2021111464A1 (en) * 2019-12-02 2021-06-10 Harman Finochem Limited A process for the preparation of highly pure valsartan

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499017A (en) * 1983-06-06 1985-02-12 Pfizer Inc. Beta-lactamase inhibiting 6-(alkoxyamino-methyl) penicillanic acid 1,1-dioxide and derivatives
PH30484A (en) * 1990-02-19 1997-05-28 Ciba Geigy Acy compounds pharmaceutical composition containing said compound and method of use thereof
JPH05105698A (ja) * 1991-06-13 1993-04-27 Takeda Chem Ind Ltd ホスホン酸誘導体、その製造法および用途
CN1143908A (zh) 1994-03-17 1997-02-26 西巴-盖尔基股份公司 利用哇尔沙通(valsartan)治疗糖尿病型肾病
MX9707683A (es) 1995-04-07 1997-12-31 Novartis Ag Composiciones de combinacion que contienen benazepril o benazeprilat y valsartan.
AU7213296A (en) 1995-10-06 1997-04-30 Ciba-Geigy Ag At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
IT1301759B1 (it) * 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
CA2415962C (en) 2000-07-19 2010-07-06 Novartis Ag Valsartan salts

Also Published As

Publication number Publication date
CY1108559T1 (el) 2014-04-09
AU8967201A (en) 2002-01-30
JP4102664B2 (ja) 2008-06-18
KR20030015888A (ko) 2003-02-25
US20140073677A1 (en) 2014-03-13
HU229280B1 (en) 2013-10-28
CN1680341A (zh) 2005-10-12
EP1313714B1 (en) 2008-08-27
US20070149587A1 (en) 2007-06-28
CA2415962C (en) 2010-07-06
CN100413852C (zh) 2008-08-27
SI1313714T1 (sl) 2009-02-28
CN1216873C (zh) 2005-08-31
WO2002006253A1 (en) 2002-01-24
EP1313714A1 (en) 2003-05-28
MY152846A (en) 2014-11-28
CN1443176A (zh) 2003-09-17
ES2309090T3 (es) 2008-12-16
PT1313714E (pt) 2008-11-03
MY136446A (en) 2008-10-31
ATE406355T1 (de) 2008-09-15
SK287558B6 (sk) 2011-02-04
PL360737A1 (en) 2004-09-20
AR069374A2 (es) 2010-01-20
IL153882A (en) 2009-09-01
PE20020613A1 (es) 2002-08-07
US8278339B2 (en) 2012-10-02
DE60135560D1 (de) 2008-10-09
CA2415962A1 (en) 2002-01-24
JP2004504307A (ja) 2004-02-12
KR100529658B1 (ko) 2005-11-21
AR032758A1 (es) 2003-11-26
BR0112665A (pt) 2003-06-24
MXPA03000525A (es) 2003-05-14
NZ523557A (en) 2004-12-24
CZ2003117A3 (cs) 2003-05-14
US9499499B2 (en) 2016-11-22
HUP0300731A3 (en) 2006-05-29
NO20030232L (no) 2003-01-17
ZA200300285B (en) 2004-03-25
IL153882A0 (en) 2003-07-31
HUP0300731A2 (hu) 2003-09-29
US20080293791A1 (en) 2008-11-27
SK552003A3 (en) 2003-07-01
RU2275363C2 (ru) 2006-04-27
DK1313714T3 (da) 2008-12-15
ECSP034436A (es) 2003-03-10
US20120329844A1 (en) 2012-12-27
AU2001289672B2 (en) 2005-12-08
US20030207930A1 (en) 2003-11-06
NO326504B1 (no) 2008-12-15
NO20030232D0 (no) 2003-01-17
CZ303389B6 (cs) 2012-08-29
PL205715B1 (pl) 2010-05-31

Similar Documents

Publication Publication Date Title
AU8967201A (en) Valsartan salts
EP1349851A4 (en) COMPOUNDS
AU7847201A (en) Tetrazole derivatives
AU2405002A (en) Dehalogeno compounds
AU7440101A (en) Novel tetrazole derivatives
GB0015900D0 (en) New salt form
GB0005200D0 (en) New salt form
AU146698S (en) Reel
GB0018306D0 (en) Compounds
GB0014642D0 (en) Compounds
GB0006454D0 (en) Compounds
GB0005576D0 (en) Compounds
GB0005574D0 (en) Compounds
GB0006800D0 (en) Compounds
GB0005387D0 (en) Compounds
GB0014641D0 (en) Compounds
GB0006457D0 (en) Compounds
GB0015902D0 (en) Compounds
GB0015863D0 (en) Compounds
GB0015853D0 (en) Compounds
GB0004053D0 (en) Compounds
GB0003637D0 (en) Compounds
GB0003634D0 (en) Compounds
GB0015852D0 (en) Compounds
GB0014823D0 (en) Compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140717